Health Catalyst, Inc. (HCAT) Q3 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A session reveal several positive indicators: a slight revenue increase, improved EBITDA, successful client acquisitions, and optimistic 2025 growth expectations. Despite some integration risks and lack of shareholder return plans, the company's strong pipeline, international growth, and strategic acquisitions bolster the outlook. The positive sentiment is supported by management's confidence in achieving double-digit growth and significant EBITDA growth in 2025. The lack of negative guidance adjustments or major financial disappointments further supports a positive stock price movement prediction.
Key Financial Performance
Total Revenue $76.4 million, an increase of 3% year-over-year.
Adjusted EBITDA $7.3 million, an increase of $5.3 million year-over-year.
Technology Revenue $48.11 million, representing 6% growth year-over-year.
Professional Services Revenue $27.7 million, roughly flat year-over-year.
Total Adjusted Gross Margin 48%, an increase of approximately 70 basis points year-over-year.
Adjusted Technology Gross Margin 65%, a decrease of approximately 330 basis points year-over-year due to upfront costs associated with the deployment of Ninja Universe.
Adjusted Professional Services Gross Margin 17%, an increase of approximately 550 basis points year-over-year.
Adjusted Total Operating Expenses $29 million, representing 38% of revenue, down from 44% in Q3 2023.
Adjusted Net Income per Share $0.07, based on 60.4 million shares.
Cash, Cash Equivalents, and Short-term Investments $387.2 million, up from $308.3 million in Q2 2024.
Outstanding Convertible Notes $230 million due in April 2025.
Initial Term Loan $125 million.
Operating Cash Flow $18.1 million through Q3 2024.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launch: Health Catalyst has introduced the Ignite interoperability platform, which is designed to enhance data management and analytics capabilities for healthcare organizations.
Client Partnership Expansion: Health Catalyst has expanded its partnership with Wisconsin Statewide Health Information Network (WISHIN) to migrate technology and services to the Ninja Universe platform.
New Client Acquisition: Health Catalyst has signed a new partnership with CyncHealth to utilize the Ninja Universe solution. Ortho Nebraska has also signed a new partnership with Health Catalyst for data and analytics infrastructure.
Market Positioning: Health Catalyst anticipates a return to double-digit revenue growth in 2025, supported by a robust pipeline and improving health system operating margins. The company expects to achieve net new platform subscription additions in the low 20s for 2024, marking the best year in its history for this metric.
Operational Efficiency: Health Catalyst reported total revenue of $76.4 million for Q3 2024, exceeding guidance, with adjusted EBITDA of $7.3 million. The company has improved its adjusted total operating expenses to 38% of revenue, down from 44% in Q3 2023.
Strategic Acquisition: Health Catalyst has signed a definitive agreement to acquire Intraprise Health for $43 million, enhancing its cybersecurity capabilities.
Strategic Shift: The company is focusing on higher-margin solutions in its pipeline, which has positively impacted adjusted EBITDA.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macroeconomic Challenges: The company discussed the impact of macroeconomic challenges, including inflation and the interest rate environment, which could affect client acquisition and retention.
Tight Labor Market: The tight labor market was mentioned as a potential challenge that could impact operational efficiency and service delivery.
Supply Chain Issues: There were references to ongoing supply chain challenges that could affect project timelines and costs.
Revenue Recognition Delays: Delays in revenue recognition for international contracts and health information exchange clients were noted, which could impact quarterly revenue expectations.
Cybersecurity Risks: The acquisition of Intraprise Health was highlighted as a response to increasing cybersecurity risks, indicating a focus on enhancing security measures for clients.
Client Demand Fluctuations: The company acknowledged fluctuations in client demand, particularly in relation to higher-margin solutions, which could affect future bookings and revenue.
Operating Expenses: There are anticipated increases in operating expenses, particularly in Q4, due to seasonal factors and resource allocation for professional services.
Acquisition Integration Risks: The integration of acquired companies poses risks related to operational efficiency and achieving expected synergies.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: 2024 revenue is anticipated to be between $305 million and $311 million.
Adjusted EBITDA Expectations: 2024 adjusted EBITDA is raised to between $25 million and $27 million.
Bookings Expectations: Reiterating full year 2024 bookings expectations, including net new platform subscription client additions in the low 20s and a dollar-based retention rate between 100% and 106%.
Acquisition Strategy: Signed a definitive agreement to acquire Intraprise Health for $43 million, focusing on enhancing cybersecurity capabilities.
Growth Strategy: Expecting top line growth to accelerate back to double digits in 2025.
Client Migration: Continuing to migrate existing clients to the Ignite platform, with strong demand for additional applications.
Q4 2024 Revenue Guidance: Expect total revenue between $78 million and $84 million.
Q4 2024 Adjusted EBITDA Guidance: Expect adjusted EBITDA between $6.8 million and $8.8 million.
2025 Growth Expectations: Anticipate approximately 50% growth in adjusted EBITDA in 2025 compared to 2024.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: Health Catalyst has not announced any share buyback program or dividend program during this earnings call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the outlook for 2025 and the importance of the fourth quarter for bookings?
A:Management expressed confidence in achieving double-digit growth in 2025, highlighting three building blocks: new client additions, expanding with existing clients, and inorganic activities. They noted a strong pipeline and the importance of Q4 for setting up next year's performance.
Q:Are you expecting a similar bookings mix in 2024, particularly from international and information exchange customers?
A:Management is encouraged by strong performance in international growth and health information exchange opportunities, noting that these tend to be higher profit margin expansions despite initial implementation complexities.
Q:Can you clarify the nature of the non-recurring services contracts and their relation to existing or new customers?
A:Management indicated that non-recurring services contracts are primarily with existing clients, both in the U.S. and internationally, and often include a services component accompanying technology revenue.
Q:What synergies does the recent acquisition have with Health Catalyst's core platform?
A:Management highlighted the importance of security as a key area of focus for clients, noting that the acquisition allows them to offer enhanced security solutions, which aligns with client needs.
Q:What are the expectations regarding elevated costs related to TEMS contracts?
A:Management clarified that while they are seeing meaningful margin improvement in established TEMS areas, new areas like ambulatory operations are still being learned, and costs may be higher initially.
Q:What is the impact of the recent sale of ambulatory assets by Steward on revenue expectations?
A:Management confirmed that they received full repayment from Steward after the sale of assets and continue to include expected revenue from the ongoing contract in their guidance.
Q:What are the expectations for EBITDA growth in 2025?
A:Management expressed confidence in achieving approximately 50% EBITDA growth in 2025, citing factors like gross margin leverage and operating efficiencies.
Q:How is the hybrid model affecting client interactions and sales?
A:Management noted a successful hybrid model, combining face-to-face quarterly business reviews with regular virtual follow-ups, which has strengthened client relationships.
Q:What is the strategy for acquiring new clients and expanding existing relationships?
A:Management emphasized the importance of cross-selling adjacent solutions to existing clients and leveraging established relationships to drive growth.
Q:Are there any capabilities that Health Catalyst wishes to offer but currently lacks?
A:Management previously identified security as a gap but noted that the recent acquisition allows them to address this need.
Q:What is the anticipated timeline for go-lives with new clients?
A:Management indicated that while new client implementations may take longer due to complexity, they remain confident in the predictability of revenue once clients are live.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact timing and pacing of go-lives for new clients, indicating that while they expect a higher number of clients, the complexity of implementations could affect timelines.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CyncHealth
Ignite platform
Professional
RD sale
St
Utah
Wisconsin
advantage
area experience
asset Health
building block
client area
client contract
client spectrum
color
confidence
cybersecurity
election
engine
expansion client
expansion contract
health care
health information
incentive
information exchange
innovation
integration playbook
motion
platform subscription
repayment
return digit
review
rhythm
sale marketing
security infrastructure
subsegment
synergy
term implementation
track
work
HCAT Transcript
Earnings call transcript: Health Catalyst beats Q1 2025 EPS forecast, stock rises
Unknown5-7
The earnings call presents mixed signals: the company reports revenue growth and exceeded EBITDA guidance, but faces macroeconomic and competitive pressures. The share repurchase program is positive, but the decline in gross margins and cash reserves, coupled with uncertain economic conditions, offset this. The Q&A indicates confidence in new client acquisition and tech margin improvement, but management's vague responses on Medicaid cuts raise concerns. Overall, the positive aspects are balanced by significant risks and uncertainties, leading to a neutral sentiment.
Health Catalyst, Inc. (HCAT) Q3 2024 Earnings Call Transcript
Positive11-7
The earnings call summary and Q&A session reveal several positive indicators: a slight revenue increase, improved EBITDA, successful client acquisitions, and optimistic 2025 growth expectations. Despite some integration risks and lack of shareholder return plans, the company's strong pipeline, international growth, and strategic acquisitions bolster the outlook. The positive sentiment is supported by management's confidence in achieving double-digit growth and significant EBITDA growth in 2025. The lack of negative guidance adjustments or major financial disappointments further supports a positive stock price movement prediction.
Health Catalyst, Inc. (HCAT) Q2 2024 Earnings Call Transcript
Positive8-8
The earnings call highlights strong financial performance, optimistic guidance, and strategic growth initiatives. Despite some risks like revenue recognition delays and competitive pressures, the new Ignite platform and strategic acquisitions are expected to drive growth. The Q&A section reveals positive reception of new products and strong pipeline demand, indicating potential for margin improvement. The company's proactive approach to refinancing and capital deployment further supports a positive outlook. Given the overall sentiment and market dynamics, a positive stock price movement (2% to 8%) is anticipated over the next two weeks.
Health Catalyst, Inc. (HCAT) Q1 2024 Earnings Call Transcript
Neutral5-10
HCAT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
